Management and dynamic risk stratification of differentiated thyroid cancer
10.3760/cma.j.issn.1673-0860.2019.05.016
- VernacularTitle: 分化型甲状腺癌治疗管理和动态风险评估现状
- Author:
Yingcheng HUANG
1
;
Zhengjiang LI
1
Author Information
1. Department of Head and Neck Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Review
- Keywords:
Thyroid neoplasms;
Recurrence;
Risk assessment
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2019;54(5):389-393
- CountryChina
- Language:Chinese
-
Abstract:
Differentiated thyroid cancer (DTC) is the most frequently diagnosed thyroid cancer. With the development of the imaging technology and fine needle aspiration, early diagnosis rate of DTC is increasing. Most patients have favorable prognosis for DTC′s low-invasion. TNM staging is more widely used for predicting mortality than predicting recurrence. In 2008, it was suggested that recurrence risks for DTC should be assessed based on the results of dynamic monitoring treatment response. The validity of dynamic risk stratification (DRS) has been supported by different researches in various countries and DRS is recommended in 2015 American Thyroid Association Management Guidelines. Long-term DRS in patients with DTC make individual management possible.
